Roche wins Herceptin injunction against Biocon and Mylan

Roche has brought a stop to joint Biocon-Mylan marketing activities in India for their biosimilar product to compete with Herceptin.

The Delhi High Court injunction has prompted a shocked, angry reaction from the generics manufacturers, which had been set to start promoting their biosimilar this month.

"It is an extremely shocking, but not unexpected development, especially as Roche had decided not to pursue Indian patents for their breast cancer drug.

"This proceeding is an attempt by Roche to protect their market monopoly and prevent Indian patients from accessing a more affordable trastuzumab."

Biocon response statement to the media.

Related news:

Roche wins battle against India sales of generic cancer drug (Financial Times).

Roche bans rivals from comparing copycat drugs to Herceptin (Reuters).

Reference links:

Biocon's statement on Roche's legal proceedings (Biocon press release).

Mylan launches first trastuzumab biosimilar, Hertraz, in India (Mylan press release, 3rd February).